Business Wire

NTT to Study Hydrogen Transportation Through Existing Pipelines

Share

NTT Anode Energy Corporation (President and CEO: Teruyuki Kishimoto, Head Office: Minato-ku, Tokyo, NTT Anode Energy) announced a joint research and development project to study safety measures for the mass transportation of hydrogen through existing pipeline infrastructure. The study, being performed in collaboration with the National Institute of Advanced Industrial Science and Technology (President: Kazuhiko Ishimura, Chiyoda-ku, Tokyo AIST) and Toyota Tsusho Co., Ltd. (Representative Director: Ichiro Kashitani, Minato-ku, Tokyo, Toyota Tsusho), is expected to contribute to the realization of a pipeline transportation model for hydrogen that could be implemented globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220725005285/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Business Model Image (Graphic: Business Wire)

According to a paper published by the International Renewable Energy Agency, “Hydrogen has emerged as an important part of the clean energy mix needed to ensure a sustainable future.” However, the large-scale, stable transportation of hydrogen through new pipeline infrastructure faces issues including land acquisition construction costs and building time. Utilizing existing pipeline infrastructure can solve these issues, and this new study represents the next step in this model’s proof-of-concept process.

The study will examine a double-piping system in which a hydrogen pipeline is placed in an existing pipe (the “sheath pipe”) buried underground. Factors to be measured and contributed to the formulation of technical standards include:

  1. On-site investigation of hydrogen leakage detection
  2. Verification of detection of signs of abnormality
  3. Establishment of a control sequence to ensure safety
  4. Performance evaluation of various hydrogen sensors in a real-world environment

Safety measures will be investigated under the assumption of unsteady conditions including rupture accidents and natural disasters during pipeline operation. In addition to examining the safety measures necessary for such use of existing pipelines, the study will verify the profitability of such projects, including cost analysis of transportation; energy input; and economic efficiency, as compared to other hydrogen transportation means.

Based on the knowledge and data gained through this project, NTT Anode Energy and its collaborators will promote and establish technical studies on safety measures for practical use. Ultimately, the project will also support the future supply of hydrogen to urban areas (e.g., public and commercial facilities, data centers and communications buildings; fuel cell vehicles; hydrogen stations, etc.), supply through pipelines utilizing communication pipelines (e.g., cable tunnels) and will contribute to the development of smart cities and the establishment of hydrogen supply means through pipelines in regions with a view to a society that consumes a large amount of hydrogen through the development of CO2-free hydrogen.

This project is being conducted in accordance with the "Research and development for the full-scale popularization of ultra-high pressure hydrogen infrastructure/Research and development for international development, international standardization, etc./Research and study for the examination of technical standards for hydrogen supply infrastructure, etc." of the New Energy and Industrial Technology Development Organization.

Primary Areas of Research by Collaborator

NTT Anode Energy

  • Hydrogen leakage detection;
  • Abnormal sign detection;
  • Hydrogen sensors investigation;
  • Investigation of residual hydrogen concentration at the time of hydrogen leakage; and
  • Investigation of explosion effect of manhole cover

AIST

  • Investigation of fire flame behavior caused by the ignition of leaked hydrogen in a simulated double piping system

Toyota Tsusho

  • Clarification of unit costs through verification of equipment, installation and safety costs; and
  • Verification of advantageous conditions and business establishment requirements of pipeline transportation

About NTT Anode Energy Group

As a company focused on leveraging the information communications technology and DC power supply technologies of the NTT Group in pursuit of “smart energy” business opportunities, NTT Anode Energy is working to develop and deliver energy solutions that make more sophisticated and efficient use of distributed energy resources such as renewable power generation facilities and storage batteries. In this way, it can fully express the unique synergies of the NTT Group. Through these efforts, we aim to work with partner companies to create new energy distribution mechanisms to help to revitalize industries and shape a more sustainable society.

NTT and the NTT logo are registered trademarks or trademarks of NIPPON TELEGRAPH AND TELEPHONE CORPORATION and/or its affiliates. All other referenced product names are trademarks of their respective owners. © 2022 NIPPON TELEGRAPH AND TELEPHONE CORPORATION

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Stephen Russell
Wireside Communications®
For NTT
+1-804-362-7484
srussell@wireside.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kapruvia ® approved in Switzerland with additional regulatory decisions expected in H2 202219.8.2022 07:00:00 CEST | Press release

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia® will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients. Swissmedic approval for Kapruvia® follows approvals by the U.S. Food and Drug Administration, by the European Medicines Agency, by the UK Medicines and Healthcare products Regulatory Agency, as well as by Health Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005552/en/ “The approval of Kapruvia® in Switzerland is the next step on our journey to bring this breakthrough treatment to hemodialysis patients living with CKD-associated pruritus around the world,” said Dr. Klaus Henning Jensen, Chief Medical Officer of CSL Vifor. “There is a

European Commission Approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the Treatment of Multiple Types of Cancer19.8.2022 04:47:00 CEST | Press release

Celltrion Healthcare announced today that the European Commission (EC) has approved Vegzelma™ (CT-P16), a biosimilar bevacizumab referencing EU-approved Avastin®, for the treatment of metastatic breast cancer, non-small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer and cervical cancer. “The European Commission’s approval of Vegzelma™ will increase access to treatment for patients living with certain types of cancer at an affordable price,” said Kevin Byoung Seo Choi, Senior Vice President and Head of Marketing Division at Celltrion Healthcare. “With proven similarities in efficacy and safety compared to the reference product Avastin®, Vegzelma™ will be available to treat some of the most commonly diagnosed cancers, which collectively affect hundreds of thousands of European patients each year.” The EC approval of Vegzelma™ follows the recommendation for marketing authorisation issued by the Committee for Medi

Dermaliq Therapeutics announces first patient dosed in Phase 1b/2 trial evaluating DLQ02 for treatment of plaque psoriasis18.8.2022 18:27:00 CEST | Press release

Dermaliq Therapeutics, Inc. (Dermaliq), a private, clinical stage pharmaceutical company with a focus on dermatology, today announced first patient dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ02 in patients with plaque psoriasis. “DLQ02 evaluates for the first time hyliQTM, a novel platform technology in dermatology to create best in-class topical therapies with superior bioavailability,” said Betsy Hughes-Formella, PhD, Chief Scientific Officer at Dermaliq. “Calcineurin inhibitors for the treatment of psoriasis are a standard of care when given orally, albeit being associated with significant risk for systemic side effects. DLQ02 is designed to overcome the challenges of topical delivery of this drug class with reduced risk profiles. We are convinced DLQ02 has the potential to transform topical psoriasis therapy for millions of patients.” The r

Aero Secures $65M in Series B Financing to Accelerate the Future of Premium Air Travel18.8.2022 18:00:00 CEST | Press release

Aero Technologies, Inc. the next-generation premium air travel company, which serves routes in both the US and Europe, today announced a $65M capital raise, $50M in Series B funding and $15M in convertible notes, for a total post-money valuation of $300M. The funding round was co-led by AlbaCore Capital Group, one of Europe’s leading alternative investment firms, and returning investors Expa and Keyframe Capital, with new investment from Capital One Ventures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005095/en/ (Photo: Business Wire) Inspired by the golden age of aviation and designed for modern life, Aero is redefining semi-private air travel. Aero serves premium leisure travelers through private terminals, enriching the experience with personalized Concierge services - from booking to touchdown. With its fleet of sleek, black planes, Aero offers elevated, effortless guest experiences to curated destinations with

Veristat is Recognized on the 2022 Inc. 5000 List of America’s Fastest-Growing Private Companies18.8.2022 15:49:00 CEST | Press release

Veristat, global experts in clinical development, registration and post-marketing solutions proudly announces its recognition once again by Inc. Magazine as one of the 5000 fastest-growing private companies in the United States. Since its first appearance on the list in 2015, Veristat has significantly expanded in size, geographic reach and service offering to swiftly guide novel therapies through their clinical development process to regulatory approval and commercialization. Veristat’s team of scientific experts works collaboratively with clients in the biotech and pharmaceutical industries to overcome the many challenges associated with bringing to market products that address current medical shortcomings and maintain their good standing. “Being recognized as one of America’s Fastest-Growing Private Companies is a testament to Veristat’s ability to deliver innovative solutions, bold thinking and versatile engagement models to our clients,” stated Patrick Flanagan, Chief Executive Of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom